(0.36%) 5 118.38 points
(0.43%) 38 403 points
(0.49%) 16 006 points
(-1.68%) $82.44
(4.84%) $2.02
(0.20%) $2 352.00
(0.20%) $27.59
(4.20%) $960.85
(-0.22%) $0.933
(-0.35%) $10.99
(-0.54%) $0.796
(1.69%) $93.43
45.99% $ 0.0200
Live Chart Being Loaded With Signals
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases...
Stats | |
---|---|
Tagesvolumen | 23 215.00 |
Durchschnittsvolumen | 330 263 |
Marktkapitalisierung | 10.96M |
EPS | $-0.175 ( 2023-06-29 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-05-24 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0200 |
ATR14 | $0.00100 (5.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-17 | Ji Henry | Buy | 19 500 | Common Stock |
2023-03-17 | Ji Henry | Sell | 195 | Put Option (obligation to buy) |
2021-12-31 | Janda Kim | Buy | 0 | |
2022-12-21 | Ji Henry | Buy | 300 | Common Stock |
2022-12-02 | Ji Henry | Buy | 200 | Common Stock |
INSIDER POWER |
---|
99.97 |
Last 96 transactions |
Buy: 40 331 586 | Sell: 980 682 |
Sorrento Therapeutics Inc Korrelation
10 Am meisten positiv korreliert | |
---|---|
INCR | 0.893 |
RPRX | 0.888 |
GCBC | 0.882 |
HYRE | 0.875 |
IXHL | 0.875 |
SPFI | 0.863 |
MICS | 0.862 |
KTTA | 0.861 |
WATT | 0.857 |
BWB | 0.853 |
10 Am meisten negativ korreliert | |
---|---|
ESCA | -0.906 |
BREZ | -0.903 |
BRLI | -0.886 |
OPRA | -0.882 |
ITAQU | -0.882 |
AUPH | -0.882 |
GRIL | -0.877 |
PBBK | -0.874 |
ESPO | -0.873 |
CNGL | -0.873 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Sorrento Therapeutics Inc Finanzdaten
Annual | 2022 |
Umsatz: | $62.84M |
Bruttogewinn: | $29.39M (46.77 %) |
EPS: | $-1.330 |
FY | 2022 |
Umsatz: | $62.84M |
Bruttogewinn: | $29.39M (46.77 %) |
EPS: | $-1.330 |
FY | 2021 |
Umsatz: | $52.90M |
Bruttogewinn: | $39.87M (75.37 %) |
EPS: | $-1.450 |
FY | 2020 |
Umsatz: | $39.99M |
Bruttogewinn: | $30.05M (75.14 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
Sorrento Therapeutics Inc
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.